Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The idiotype immunoglobulin refers to an immunoglobulin's distinctive set of antigenic determinants (idiotopes) found in the variable regions of its heavy and light chains. These arise due to gene rearrangement and somatic mutation during B cell development, endowing each antibody with a unique surface for antigen binding. Idiotypes are crucial in immune recognition and are exploited as therapeutic targets, particularly in B cell lymphoma, where each malignant clone expresses a unique idiotype that can serve as a tumor-specific antigen. They can also serve as surrogate antigens in vaccine approaches, leveraging anti-idiotype responses to induce immunity. However, their use poses challenges due to variability and the potential for immune-mediated adverse effects.
Immune targeting of malignant B cell clone via idiotype antigen; Induction of anti-idiotype immune response (vaccine strategy); Immunomodulation through anti-idiotype network.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Idiotype immunoglobulin.